‘Pharma resistance’ to battle superbugs
24 September 2020
A group of pharmaceutical giants, biotech companies, industry peak bodies and the CSIRO have banded together to form an alliance to combat the “market failure” that inhibits the development of novel antibiotics to fight superbugs.
The Australian Antimicrobial Resistance Network — known as AAMRNet — will work to secure reforms aimed at incentivising antibiotic research and development in the face of an escalating crisis in which modern medicine is running out of options to treat drug-resistant infections.
Further reading: The Australian
Author(s): Natasha Robinson
Healthy Patients Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
